New study aims to prevent dangerous ketosis in type 1 diabetes patients with kidney disease
NCT ID NCT07325201
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how to safely use a type of diabetes drug (SGLT1&2 inhibitor) in people with type 1 diabetes and mild to moderate chronic kidney disease. The goal is to find out what increases the risk of a serious condition called diabetic ketoacidosis (DKA). About 80 adults will wear continuous glucose and ketone monitors and take the study drug for nine months. The results will help create better reports to warn patients and doctors about ketosis risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
International Diabetes Center
Minneapolis, Minnesota, 55416, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••